Enzalutamide

SAN FRANCISCO — Rucaparib significantly improved radiographic PFS compared with physician’s choice of therapy for men with chemotherapy-naive metastatic castration-resistant prostate cancer, according to randomized phase 3 study results.

SAN FRANCISCO — The addition of talazoparib to first-line enzalutamide extended imaging-based PFS among men with metastatic castration-resistant prostate cancer, according to results of the randomized phase 3 TALAPRO-2 study.

A randomized phase 3 trial that assessed rucaparib for certain men with advanced prostate cancer met its primary endpoint of improved PFS, according to topline data released by the agent’s manufacturer.

Both abiraterone and enzalutamide appeared to increase risk for metabolic and cardiovascular adverse events among older men with advanced prostate cancer who previously underwent androgen deprivation therapy, according to study results.

Enzalutamide monotherapy demonstrated significant treatment response among men on active surveillance for low- or intermediate-risk localized prostate cancer, according to phase 2 study results published in JAMA Oncology.

Healio spoke with Daniel P. Petrylak, MD, about a presentation the American Urological Association meeting that focused on discontinuation rates of hormone therapy options among patients with advanced prostate cancer.

In this video, Daniel P. Petrylak, MD, discussed a presentation investigating androgen deprivation therapy plus upfront docetaxel in the treatment of patients 75 years or older with prostate cancer.

SAN FRANCISCO — Continued enzalutamide, after progression on the drug, in combination with docetaxel significantly extended PFS compared with placebo and docetaxel among men with metastatic castration-resistant prostate cancer, study results showed.

In this video, Eugene Shenderov, MD, PhD, assistant professor of oncology at Johns Hopkins Sidney Kimmel Comprehensive Cancer Center in Baltimore, MD, discussed two studies that highlight positive results from darolutamide for prostate cancer.

Abiraterone and gonadotropin-releasing hormone agonists for the treatment of prostate cancer may increase the likelihood of drug-related adverse cardiac events, according to data published in EClinicalMedicine.